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New derivatives of synthetic 5,5-diphenylhydantoin (phenytoin) were prepared by N-alkylation 
with 1,3-dibromopropane. Subsequent treatment with sodium azide led to the respective azide. 
Reaction of the azide with phenylacetylene and 2-hydroxy-3-butyne and oxidation of the resulting 
alcohol with MnO2 resulted in three triazolic compounds that were evaluated in vitro for their 
antiviral activity against human metapneumovirus (HMPV). 5,5-Diphenyl-3-[3-(4-phenyl-1H-
1,2,3-triazol-1-yl)propyl]imidazolidine-2,4-dione was the most active of the three compounds 
tested, with selectivity index of 129.87, even higher than ribavirin, the control substance. The three 
compounds showed activity in the early stages of viral replication presenting virucidal activity 
and binding to cellular receptors, preventing the adsorption of viral particles. These compounds 
showed higher activity in both experiments, inhibiting 98.3% of infection as virucidal and 98.9% 
when interacting with cellular receptors. Furthermore, they showed 73.8% of activity during the 
penetration of HMPV particles into cells. The derivative 3-{3-[4-(1-hydroxyethyl)-1H-1,2,3-triazol-
1-yl]propyl}-5,5-diphenylimidazolidine-2,4-dione presented a mild anti-HMPV activity, with 
selectivity index of 2.74. 3-[3-(4-acetyl-1H-1,2,3-triazol-1-yl)propyl]-5,5-diphenylimidazolidine-
2,4-dione inhibited less than 50% of HMPV replication.
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Introduction
Human metapneumovirus (HMPV) is a negative-sense, 
single-stranded RNA virus first isolated in 2001 by van 
den Hoogen and colleagues1,2 in previously virus-negative 
nasopharyngeal aspirates from children with respiratory 
tract infections. It has been recognized as a common cause 
of respiratory infections in children, immunocompromised 
and elderly populations.3 
HMPV causes occasional upper respiratory tract 
infections, although lower respiratory tract infections 
can result in bronchiolitis, pneumonitis and asthma 
exacerbations.4,5
In Brazil, the burden of HMPV infections has been 
demonstrated by several scientists.6-11 Currently, there is no 
antiviral therapy available for prevention or treatment of 
HMPV infection, with the exception of ribavirin, although 
its activity is still questionable.12
Many hydantoin (imidazolidine-2,4-dione) derivatives 
have pharmacological activities (anticonvulsant, antifungal, 
antibacterial and antiparasitic),13,14 related to the substituents 
in positions 3 or 5 of the imidazolic-like ring.
Phenytoin (5,5-diphenyl-2,4-imidazolidindione 
or 5,5-diphenylhydantoin) belongs to a group of anti-
epileptic drugs with clinical use in cases of partial and 
generalized seizures. It displays various effects such as 
inhibition of sodium, potassium and calcium channels in 
the neurons membrane, changes in local concentrations 
of neurotransmitters such as GABA, acetylcholine and 
noradrenaline and decreased neuronal excitation in 
general.13 Furthermore, a number of phenytoin derivatives 
have also been studied and many of them have shown 
Mendes et al. 3Vol. 27, No. 1, 2016
interesting pharmacological properties, including 
anticonvulsivant,15 antimicrobial16 and anti-arrhythmic.17 
Due to its properties, this molecule was chosen as lead 
for the obtention of new 1,2,3-triazole derivatives in this 
work. 1,2,3-Triazole is an important nucleus, which can 
be easily obtained by a copper catalyzed alkyne-azide 
cycloaddition reaction (vide infra). It is present in many 
compounds with various pharmacological activities, 
including antiviral.18 Thus, we envisaged that new 
molecules containing both phenytoin and 1,2,3-triazole 




Commercially available reagents and solvents were 
purchased from Merck, Aldrich Chemical Co., Reagen, 
Fluka, Chemicals Group, Vetec and Ecibra and used without 
further purification. All compounds obtained in this work 
were obtained as solids and purified by recrystallization. 
Melting points were determined in a Köfler block and are 
uncorrected. The infrared spectra (IR) were recorded in a 
Bomem Hartmann & Brawn MB-100 spectrometer. Nuclear 
magnetic resonance (NMR) 1H NMR spectra (300 MHz) and 
13C NMR (75.46 MHz) were recorded in a Varian Mercury 
plus (7.05 T) spectrometer. The NMR experiments were 
referenced to tetramethylsilane (TMS) (d 0.0) as internal 
standard for 1H, and CDCl3 (d 77.0) and dimethylsulfoxide 
(DMSO) (d 39.7) for 13C, respectively. The letters s, t, q 
and m are used to indicate a singlet, triplet, quadruplet and 
multiplet, respectively. High resolution electrospray (ESI) 
mass spectra (MS) were obtained on a Micro TOF-Bruker 
Daltonics instrument and IR spectra were recorded on a 
Varian 640-IR spectrometer. Compounds were analyzed 
by IR, 1H NMR, 13C NMR and high resolution ESI mass 
spectra giving data consistent with the proposed structures.
2-Hydroxy-1,2-diphenylethanone (3)19
A solution of potassium cyanide (6.63 g; 0.10 mol) 
in distilled water (50 mL) was added to a solution of 
benzaldehyde (50.0 g; 47.5 mL; 0.47 mol) in 96% ethanol 
(65 mL). The mixture was refluxed for 30 min and then 
cooled in an ice bath. The crude product was filtered, 
washed with cold distilled water and recrystallized from 
hot ethanol. White crystals were obtained (27.5 g; 0.13 mol, 
55%); mp 136-138 ºC; IR (KBr) ν / cm-1 3414, 3377, 
1678, 1263, 1092, 755, 595; 1H NMR (300 MHz, CDCl3) 
d 7.90-7.94 (m, 2H), 7.48-7.55 (m, 2H), 7.24-7.41 (m, 6H), 
5.96 (s, 1H), 4.58 (broad s, 1H); 13C NMR (75.46 MHz, 
CDCl3) d 198.8, 138.9, 133.8, 133.3, 129.1, 129.0, 128.6, 
128.5, 127.7, 76.1.
Benzil (4)19
A mixture of 2-hydroxy-1,2-diphenylethanone (3) 
(27.5 g; 0.13 mol) and concentrated nitric acid (140 mL) 
was refluxed for 2 h, until nitrogen oxide gas evolution 
stopped. The reaction mixture was poured into cold distilled 
water (400 mL), stirred and allowed to freeze for 24 h. 
After vacuum filtration, the crystals were washed with cold 
distilled water to completely remove the nitric acid. The 
product recrystallized from hot ethanol (66 mL) forming 
crystals as pale yellow needles (26.16 g; 0.12 mol; 96%); 
mp 94-97 °C; IR (KBr) ν / cm-1 3551, 3477, 3416, 1676, 
1657, 1211, 998, 875, 794, 718, 642; 1H NMR (300 MHz, 
CDCl3) d 7.96-8.00 (m, 4H), 7.63-7.70 (m, 2H), 7.48-7.54 
(m, 4H); 13C NMR (75.46 MHz, CDCl3) d 194.5, 134.8, 
132.7, 129.7, 128.9.
5,5-Diphenylimidazolidine-2,4-dione (phenytoin) (1)19
Potassium hydroxide 70% (8.1 mL), urea (2.30 g, 
0.04 mol) and benzil 4 (4.20 g, 0.02 mol) were added 
to ethanol (45 mL) in a round-bottom flask. The dough 
formed was refluxed for 3 h and became clear by heating. 
Then cold distilled water was added (100 mL) and the 
diphenylacetylenediurein precipitate was discarded. A 
solution of 50% sulfuric acid was added to the filtrate, 
with stirring, until acidic pH. The precipitate so formed 
was filtered under vacuum and washed with cold distilled 
water. The crystals were recrystallized from a solution of 
hot distilled water (4.5 mL) and sodium hydroxide (1.88 g, 
0.05 mol) and treated with activated charcoal (0.3 g). After 
filtration on Celite®, a solution of 50% sulfuric acid was 
added to the filtrate until precipitation of the product as a 
beige colored solid, which was filtered and dried in oven at 
100 ºC, yielding a beige powder (3.28 g, 0.013 mol, 65%); 
mp 297-300 ºC; IR (KBr) ν / cm-1 3273, 3208, 1773, 1741, 
1718, 1494, 1449, 1401, 1235, 1015, 787, 641; 1H NMR 
(300 MHz, DMSO-d6) d 11.13 (s, 1H), 9.33 (s, 1H), 
7.31-7.44 (m, 10H); 13C NMR (75.46 MHz, DMSO-d6) d 
174.9, 156.1, 139.9, 128.6, 128.1, 126.7, 70.3.
3-(3-Bromopropyl)-5,5-diphenylimidazolidine-2,4-dione (5)
DBU (1,8-diazabicycloundec-7-ene, 3.80 mL; 
25.0 mmol) was added dropwise to a solution of 
5,5-diphenylimidazolidine-2,4-dione 1 (6.30 g; 25.0 mmol) 
in CH2Cl2 (30 mL). After stirring for 30 minutes at room 
temperature, 1,3-dibromopropane (5.1 mL; 50.0 mmol) 
was added and the reaction mixture refluxed for 3 h. Then 
CH2Cl2 (50 mL) was added to the reaction mixture and the 
organic phase was washed with distilled water (20 mL), 
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brine (20 mL), dried over Na2SO4 and concentrated under 
vacuum. The crude residue was purified by recrystallization 
(EtOH) yielding a white solid (6.50 g; 17.4 mmol; 69%); 
mp 140-144 °C; IR (KBr) ν / cm-1 3454, 3406, 3220, 
3099, 1772, 1706, 1494, 1417, 1255, 789, 700, 693, 518; 
1H NMR (300 MHz, CDCl3) d 7.36 (s, 10H), 7.14 (s, 1H), 
3.72 (t, 2H, J 6.9), 3.34 (t, 2H, J 6.7), 2.16-2.25 (m, 2H); 
13C NMR (75.46 MHz, CDCl3) d 173.2, 156.7, 138.9, 128.7, 
128.5, 126.6, 70.0, 37.6, 31.0, 29.5; HRMS m/z, calc. for 
C18H18BrN2O2 [M + H]+: 373.0552; found: 373.0549. 
3-(3-Azidopropyl)-5,5-diphenylimidazolidine-2,4-dione (6)
Sodium azide (5.10 g; 78.6 mmol) was added to a mixture 
of 3-(3-bromopropyl)-5,5-diphenylimidazolidine-2,4-dione 
5 (9.80 g; 26.0 mmol) in ethanol (80 mL) and distilled water 
(16 mL). The white mixture was stirred under reflux for 35 h. 
Ethanol was evaporated and the aqueous phase extracted with 
CH2Cl2 (80 mL). The organic layer was washed with distilled 
water (2 × 40 mL), brine (40 mL), dried over Na2SO4, and 
concentrated under vacuum. The yellowish oil was dissolved 
in ethyl acetate, treated with charcoal and filtered through 
Celite®. After solvent evaporation and purification by 
recrystallization (ethanol) a pale yellow solid was obtained 
(8.80 g; 24.3 mmol; 93%); mp 118-120 °C; IR (KBr) ν / cm-1 
3448, 3413, 3222, 3171, 3094, 2099, 2079, 2053, 1770, 1708, 
1495, 1245, 759, 534; 1H NMR (300 MHz, CDCl3) d 7.47 
(s, 1H), 7.36 (s, 10H), 3.65 (t, 2H, J 6.8), 3.30 (t, 2H, J 6.6), 
1.85-1.94 (m, 2H); 13C NMR (75.46 MHz, CDCl3) d 173.3, 
156.9, 138.9, 128.6, 128.4, 126.6, 69.9, 48.7, 36.4, 27.3; 




Phenylacetylene (1.7 mL; 15 mmol) was added to a 
mixture of CuSO4.5H2O (3.70 g; 15.0 mmol), sodium 
ascorbate (4.50 g; 22.5 mmol) and 3-(3-azidopropyl)-5,5-
diphenylimidazolidine-2,4-dione 6 (5.00 g; 15.0 mmol) in 
a mixture of distilled water (50 mL) and CH2Cl2 (25 mL). 
The orange mixture was stirred under reflux for 24 h. To 
the reaction mixture were added CH2Cl2 (100 mL) and 
distilled water (100 mL). The organic layer was washed 
with distilled water (50 mL), brine (50 mL), dried over 
Na2SO4 and concentrated under vacuum. The pale yellow 
solid was purified by recrystallization (hexane/ethyl acetate 
1:1) yielding a beige solid (5.50 g; 12.5 mmol; 83%); mp 
190-193 °C; IR (KBr) ν / cm-1 3477, 3409, 3273, 3181, 
3116, 3087, 1769, 1712, 1493, 1446, 1424, 1383, 1347, 
1222, 1042, 792, 738, 516; 1H NMR (300 MHz, CDCl3) 
d 7.92 (s, 1H), 7.76-7.80 (m, 5H), 7.43 (s, 1H), 7.31-7.41 
(m, 10H), 4.36 (t, 2H, J 6.8), 3.65 (t, 2H, J 6.5), 2.26-2.35 
(m, 2H); 13C NMR (75.46 MHz, CDCl3) d 173.5, 156.6, 
147.6, 138.8, 130.4, 128.9, 128.7, 128.6, 128.1, 126.7, 
125.7, 120.4, 70.2, 47.4, 35.9, 29.1; HRMS m/z, calc. for 
C26H23N5O2Na [M + Na]+: 460.1749; found: 460.1755.
3-{3-[4-(1-Hydroxyethyl)-1H-1,2,3-triazol-1-yl]propyl}-5,5-
diphenylimidazolidine-2,4-dione (8)
2-Hydroxy-3-butyne (1.60 mL; 20.0 mmol) was added 
to a mixture of CuSO4.5H2O (3.70 g; 15.0 mmol), sodium 
ascorbate (4.50 g; 22.5 mmol) and 3-(3-azidopropyl)-5,5-
diphenylimidazolidine-2,4-dione 7 (5.00 g; 15.0 mmol) in 
a mixture of distilled water (50 mL) and CH2Cl2 (25 mL). 
The orange mixture was stirred under reflux for 24 h. Then, 
CH2Cl2 (100 mL) and distilled water (100 mL) were added 
to the reaction mixture. The organic layer was washed with 
distilled water (50 mL), brine (50 mL), dried over Na2SO4 
and concentrated under vacuum. The brown oil obtained 
was dissolved in ethyl acetate, treated with charcoal 
and filtered through Celite®. After solvent evaporation 
and purification by recrystallization (CH2Cl2/hexane), 
a white solid was recovered (4.00 g; 9.92 mmol; 66%); 
mp 78-81 °C; IR (KBr) ν / cm-1 3548-3238, 3464, 3418, 
3171, 2974, 2958, 2926, 1766, 1788, 1634, 1617, 1491, 
1447, 1308, 1150, 1077, 759, 529; 1H NMR (300 MHz; 
CDCl3) d 7.59 (s, 1H), 7.35-7.38 (m, 10H), 6.69 (s, 1H), 
5.05 (q, 1H, J 6.7), 4.32 (t, 2H, J 6.9), 3.63 (t, 2H, J 6.6), 
2.24-2.33 (m, 2H), 1.67 (s, 1H), 1.57 (d, 3H, J 6.7); 
13C NMR (75.46 MHz; DMSO-d6) d 173.4, 155.3, 152.7, 
139.6, 129.8, 127.8, 125.7, 120.2, 69.2, 62.6, 46.6, 40.3, 
24.7, 6.8; HRMS m/z, calc. for C22H23N5O3Na [M + Na]+: 
428.1700; found: 428.1699.
3-[3-(4-Acety l -1H -1,2,3- t r iazol -1-y l )propyl ] -5,5-
diphenylimidazolidine-2,4-dione (9)
MnO2 (0.87 g; 10.0 mmol) was added to a mixture of 
3-{3-[4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]propyl}-
5,5-diphenylimidazolidine-2,4-dione 8 (0.40 g; 1.00 mmol) 
in CH2Cl2 (20 mL). The reaction mixture was stirred at 
room temperature for 24 h. Then, it was filtered through 
Celite® and concentrated under vacuum. The pale yellow 
semi-solid was purified by recrystallization (CH2Cl2) 
yielding a white solid (0.37 g; 0.92 mmol, 92%); mp 
151-152 °C; IR (KBr) ν / cm-1 3456, 3351, 3149, 1780, 
1673 1713, 1493, 1528, 1449, 1236, 1207, 1035, 768, 
623 cm-1; 1 H NMR (300 MHz, DMSO-d6) d 9.72 (s, 1H), 
8.77 (s, 1H), 7.33-7.44 (m, 10H), 4.44 (t, 2H, J 7.0), 3.49 
(t, 2H, J 7.1), 2.55 (s, 3H), 2.10-2.20 (m, 2H); 13C NMR 
(75.46 MHz, DMSO-d6) d 191.7, 173.3, 155.2, 146.9, 
139.6, 128.6, 128.2, 127.4, 126.7, 69.2, 47.5, 35.5, 28.3, 
27.1; HRMS m/z, calc. for C22H22N5O3 [M + H]+: 404.1723; 
found: 404.1723.
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In vitro antiviral assays against HMPV
The cell culture used was LLC-MK2 (Macaca mulatta, 
monkey, rhesus) grown in Dulbecco’s modified Eagle’s 
medium (DMEM), supplemented with L-glutamine 
(3 mmol L-1), garamicin (50 mg mL-1), fungizon (2.5 mg mL-1), 
sodium bicarbonate at 0.25%, and 10% of heat-inactivated 
fetal bovine serum (FBS) and maintained at 37 °C in an 
atmosphere of 5% CO2. All experiments were carried out 
using the same amount of cells (5 × 105 cells mL-1).
A sample of HMPV NL/1/00 was kindly provided by 
ViroNovative BV, Erasmus University Rotterdam. Because 
the in vitro viral replication is dependent on trypsin, this 
enzyme was added to the culture medium for a final 
concentration of 1 μg mL-1 in all antiviral and cytotoxicity 
experiments.
The cytotoxicity assay was performed by incubating 
LLC-MK2 cell monolayers cultivated in 96-well microplates 
with two-fold serial dilutions of compounds 7, 8 and 9 in 
triplicate, for seven days at 34 °C. The cellular viability was 
further evaluated by the neutral red dye-uptake method.20 
In this experiment, the cytotoxic concentration for 20% 
of cell culture (CC20), used in the antiviral assays, and the 
cytotoxic concentration for 50% of cell culture (CC50) were 
determined for subsequent determination of the selectivity 
index (SI).
In the antiviral assay, LLC-MK2 cell monolayers 
cultivated in 48-well microplates were treated with 
compounds 7, 8 and 9 at the concentration chosen according 
to the cytotoxicity results. The wells reserved for cell 
and virus controls were not treated with the compounds. 
Afterwards, 100 µL of an HMPV suspension diluted at 
10-1 corresponding to 1.12 × 107 copies mL-1 were added 
to treated and untreated cell cultures and incubated in a 5% 
CO2 atmosphere at 34 °C for seven days. All experiments 
were carried out in triplicate. 
After incubation, the supernatant of the cell monolayers 
was removed and then lysated using guanidine thiocyanate 
buffer. The viral RNA was extracted and a real time RT-PCR 
for detection of HMPV genome was performed using 
primers that amplify a 151 bp fragment of the HMPV N 
gene, as previously described by Brittain-Long et al.21 The 
antiviral activity was evaluated comparing the number of 
copies of viral genome obtained from the supernatant of 
the cell cultures in the presence of compounds 7, 8 and 9 
with that of the virus control that was inoculated in the 
same plate in an untreated cell culture.
The dose-response curve was established starting 
from the non-cytotoxic concentrations, and the 50% 
effective dose (ED50) was defined as the concentration of 
the compounds that inhibits 50% of viral replication. The 
selectivity index (SI) was determined as the ratio of CC50 
to EC50.
Viral RNA was extracted from the cells supernatant 
lysate using the commercial kit Totally RNA™ (Applied 
Biosystems/Ambion, USA), according to the manufactory’s 
instructions.
Reverse transcription (RT-PCR) was performed in a 
10 μL reaction mixture containing 5 μL of extracted viral 
RNA and 360 nmol L-1 of the antisense primer, using 
ImProm-II Reverse Transcriptase (Promega, Madison, WI, 
USA). Real-time PCR assays were performed in a step-one 
real time PCR System (Applied Biosystems, Carlsbad, 
CA, USA) and consisted of 10 min activation at 95 °C, 
followed by 45 cycles of 15 s at 95 °C, and 60 s at 60 °C. 
Amplification was carried out in 24 μL reaction volumes, 
including 5 μL of cDNA, 900 nmol L-1 of sense primer and 
300 nmol L-1 of antisense primer, and 12 μL of Maxima 
qPCR SYBR Green (Thermo Scientific/Fermentas, 
Canada). The quantification of HMPV RNA was performed 
using a standard curve generated by the Ct (threshold cycle) 
values obtained from serial 10-fold dilutions of in vitro 
transcripts containing dilutions varying from 100 to 107 of 
the original virus stock. Each dilution was quantified using 
the Quant-IT™ DNA assay kit (Invitrogen, Carlsbad), 
which allows us to correlate the amount of DNA, i.e., the 
number of genome copies, with the Ct of each dilution. The 
results were analyzed in triplicate, and the average number 
of copies of the viral DNA was calculated.
Once the ability of compounds 7, 8 and 9 to inhibit the 
replication of HMPV was established, several experiments 
were carried out to elucidate the mechanism involved in 
their antiviral activity. The experiments were designed in 
order to demonstrate whether the activity was on the viral 
particle (virucidal), on the virus-cell interaction (receptors 
and cell entry) or in a late stage of virus replication 
(intracellular activity). 
Virucidal assay
100 µL of an HMPV suspension diluted at 10-1 were 
added to either 900 μL of compounds 7, 8 and 9 or to 
DMEM-Eagle without serum (control), according to 
Chen et al.22 All mixtures were incubated at 37 °C for 
2 h and, immediately afterwards, they were inoculated in 
LLC-MK2 cell monolayers grown in 48-well plates, which 
were incubated for seven days at 34 °C in an atmosphere 
of 5% CO2, according to well established procedures.23-25 
After incubation, the supernatant of the cell monolayers 
was removed, and then lysated using guanidine thiocyanate 
buffer. The viral RNA was extracted and real time PCR 
for HMPV was performed as described above. During the 
pre-incubation period, if the substance has any affinity for the 
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viral proteins, they will bind and that can inhibit the infection 
of the cell culture. The substance can also destroy the viral 
particle, thus when added to the cell culture, there will be no 
virus to replicate. This methodology allows us to compare 
the number of copies of viral RNA in the presence of each 
compound with the positive control (where the virus does not 
find any resistance to its replication), allowing us to establish 
a percentage of reduction based on the positive control.23-25
In order to evaluate the possible effect of compounds 7, 
8 and 9 on cell receptors, they were added to LLC-MK2 
cell monolayers, incubated at 4 °C for 1 h, washed three 
times with cold DMEM-Eagle and 100 μL of an HMPV 
suspension diluted at 10-1 were added to treated and 
untreated cell culture and incubated at 34 °C for seven days. 
After incubation, the supernatant of the cell monolayers was 
removed and lysated using guanidine thiocyanate buffer. 
The viral RNA was extracted and real time PCR for HMPV 
was performed as previously described. 
The preincubation of the cells with the compounds for 
1 h at 4 °C is to allow the interaction of the substances 
with the protein in the cell surface and this temperature 
is important so the cell surface will not be in fluid state. 
This avoids the substances to penetrate the cells and allows 
their interaction only with the cell surface proteins. After 
that period, the cells were washed to remove anything 
that does not have a strong binding to the cell surface 
proteins, so if the substance has affinity for any protein 
in the cell surface, it will remain bound. And only after 
that the virus is added. So, if the receptor for the virus, 
which is a cell surface protein, is somehow blocked by the 
substances, the virus will not infect those cells, resulting 
in a reduction of the titer, once again measured by RT-real 
time PCR, comparing to the virus control. This is also a 
well established methodology.23-26
Cell entry assay
LLC-MK2 cell monolayers were inoculated with 100 μL 
of an HMPV suspension diluted at 10-1 and incubated for 
1 h at 4 °C. After absorption, the monolayers were washed, 
treated with compounds 7, 8 and 9, followed by incubation 
for 1 h at 37 °C. Afterwards, the monolayers were washed, 
DMEM-Eagle was added and the cells were incubated at 
34 °C for seven days in an atmosphere of 5% CO2. After 
incubation, the supernatant of the cell monolayers was 
removed and lysated using guanidine thiocyanate buffer. 
The viral RNA was extracted and real time PCR for HMPV 
was performed as already described.
Intracellular assay
LLC-MK2 cell monolayers were inoculated with 100 μL 
of an HMPV suspension diluted at 10-1 and incubated at 
37 °C for 2 h, which is enough time for the viral particles to 
penetrate the cells, but not enough for the virus to start the 
translation and transduction stages. After incubation, the cell 
monolayers were washed and compounds 7, 8 and 9 added. 
Then, the cells were incubated at 37 °C for 10 h. It is well 
known that the viral cycle of the HMPV takes approximately 
12 hours, which means that after this period of infection the 
first viral particles will start to emerge from the infected 
cells. In order to evaluate any activity inside the cells, the 
experiment has to be stopped before 12 hours of incubation 
and then a comparison of the amount of RNA produced in 
this period of time is carried out in the presence and in the 
absence of the substances. After incubation, the supernatant 
of the cell monolayers was removed and these were washed 
with culture medium and lysated using guanidine thiocyanate 
buffer. The viral RNA was extracted and real time PCR for 
HMPV was performed as already described.
By conducting the cytotoxicity tests based on the 
incorporation of the vital dye neutral red, we could choose 
the concentrations of each compound to be used in antiviral 
tests. The chosen concentrations were the ones in which 
at least 80% of the cells in culture remained viable (CC20), 
which varied between 500 μg mL-1 (compounds 7 and 9) 
and 125 μg mL-1 (compound 8).
It was not possible to determine the CC50 (cytotoxic 
concentration for 50% of cells), for compounds 7 and 
9 since the percentage of viable cells at the highest 
concentration tested (500 μg mL-1) was higher than 50%. 
The CC50 value for compound 8 was 236.05 μg mL-1 
(Table 1).
Results and Discussion
Phenytoin was synthesized using the method described 
by Vogel19 (Scheme 1) in which benzaldehyde undergoes 
self-condensation followed by oxidation to benzil (4). 
Benzil condensation with urea then produces phenytoin (1) 
in good overall yield.
Structural modification of pharmacologically active 
compounds is of interest since the introduction of other 
pharmacophoric groups in the right position of these 
compounds can generate a new class of molecules with 
potential action on living organisms. In this sense, we 
envisaged the association of the phenytoin nucleus with 
triazolic rings containing different substituents, since 
some triazolic compounds have shown a broad spectrum 
of activities such as antibacterial, anticonvulsant, anti-
inflammatory, antiviral, anticancer and antitumor, among 
others.27
These triazolic rings can be easily obtained by 
cycloaddition reaction between acetylenes and azides 
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catalyzed by copper(I) salts, a process known as Huisgen 
cycloaddition.29 This reaction was studied by Huisgen in 
the 1960’s and, due to its versatility, the alkyne and azide 
groups can be incorporated into various compounds through 
many methodologies.30
In this work, several 3-substituted imidazolic-like 
compounds were prepared from synthetic phenytoin, 
aiming at potential new drugs presenting inhibitory activity 
against human metapneumovirus (HMPV). The synthetic 
methodology is straightforward and is summarized in 
Scheme 2. The title compounds (7-9) were obtained in 
good overall yields from phenytoin and the formation of the 
triazolic rings was confirmed by NMR analysis in which the 
CH protons appear between 7.5-9.0 ppm and the carbons 
between 130-150 ppm.
Regarding antiviral activity, compounds 8 and 9 showed 
a mild potential against HMPV, inhibiting 67.5% and 
42.9% of viral replication, respectively, while compound 7 
inhibited 99.9%, the same as ribavirin (Table 1).
A dose-response curve was performed in order to determine 
the ED50 values for each triazolic compound (Figure 1). 
Nevertheless, this was not possible for compound 9, since 
at the highest concentration tested it inhibited less than 50% 
of viral replication. The antiviral activity for compounds 7 
and 8 was dose-dependent, meaning that the lower the 
concentration of the compound, the lower the inhibition. 
The ED50 values were 85.89 μg mL-1 for compound 8, 
3.85 μg mL-1 for compound 7, and 1.68 μg mL-1 for ribavirin.
It was not possible to determine the selectivity index 
(SI) of compound 9, since no dose-response curve was 
made. But compounds 8, 7 and ribavirin showed SI of 
2.74, > 129.87 and > 119.04, respectively. 
Four different mechanisms of action were evaluated 
(Table 2): virucidal, interaction with cellular receptors, 
inhibition of the viral penetration and the activity in 
intracellular events (post-penetration). The occurrence of one 
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Scheme 2. (i) BrCH2CH2CH2Br, DBU, CH2Cl2, reflux, 3 h; (ii) NaN3, EtOH/H2O 20%, reflux, 35 h; (iii) PhCCH or CH3CH(OH)CCH, CuSO4.5H2O, Na 
ascorbate, reflux, 24 h; (iv) MnO2, CH2Cl2, r.t., 24 h.
Table 1. Cytotoxicity and antiviral activity of the triazolic compounds 7-9
Compound CC20a / (μg mL-1) Inhibition at CC20 / % CC50b / (μg mL-1) ED50c / (μg mL-1) SId / (CC50b/ED50c)
7 500 99.9 > 500 3.85 > 129.87
8 125 67.5 236.05 85.89 2.74
9 500 42.9 > 500 NDe NDe
Ribavirinf 50 99.9 > 200 1.68 > 119.04
a20% cytotoxic concentration; b50% cytotoxic concentration; c50% effective dose; dselectivity index; enot determined; fstandard compound.
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Regarding antiviral potential, compound 7 was the most 
active, with ED50 value of 3.85 μg mL-1, a value 22 times 
smaller than that of the second best compound (ED50 of 
85.89 μg mL-1 for compound 8). Furthermore, compound 
7 was less toxic for LLC-MK2 cells, which contributed for 
its high selectivity index (129.87).
When we studied the mechanisms of action, both 
compounds (7 and 8) showed activity in the early stages 
of HMPV replication, mainly virucidal (98.3% and 63.9%, 
respectively), interacting with the cellular receptors, thus 
preventing HMPV adsorption to cell surface (98.9% 
and 67.4%, respectively). Compound 7 also showed 
activity during the penetration of HMPV particles into 
cells, inhibiting 73.8% of viral replication. In this stage, 
compound 9 had no activity and compound 8 a mild 
one (19.3%). None of the three compounds was capable 
of inhibiting intracellular events of HMPV replication, 
unlike ribavirin, probably due to the low solubility of these 
compounds.
Conclusions
According to the results shown here, we conclude 
that compounds 7, 8 and 9 may be used as a prophylactic 
treatment for infections caused by HMPV because they act 
by preventing adsorption and penetration of viral particles 
in the host cell. Probably, its use in combination with 
ribavirin may be an alternative to minimize the action of 
the virus.
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Supplementary data are available free of charge at 
http://jbcs.sbq.org.br as PDF file.
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Figure 1. Dose-response curves of the triazolic compounds against HMPV 
(a) compound 8; (b) compound 7.
Table 2. Mechanisms of action of compounds 7, 8 and 9
Virucidala Receptora Penetrationa Intracellulara
7 98.3 98.9 73.81 0
8 63.9 67.4 19.33 0
9 43.3 46.4 0 0
Ribavirin 0 0 0 99.9
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